a single puff or more of a cigarette since the quit day. We then examined point-prevalence abstinence at end of treatment (EOT). In an effort to reduce multiple comparisons, we did not evaluate follow-up post EOT in the present investigation, in part because results from single marker variants and bupropion response at these end points have been reported in previous publications (36, 41–44).
